NOWHERE IS INDIA'S EPITHET-pharmacy of the world-more apt than in the case of some big pharmaceutical companies. One such company is Aurobindo Pharma, which has steadily grown over the past 10 years to become the second-biggest Indian pharma company behind only Sun Pharma. Its consolidated revenues grew from ₹4,550.56 crore in FY12 to ₹23,366.55 crore in FY22. Ten years ago, it was placed sixth (see table 'Coming from Behind").
So, how did the Hyderabad headquartered company reach such stratified air? Aurobindo has adopted a strategy of focussing on its forte of biosimilars (medicines that are highly similar to their branded reference medicines) along with gradually advancing in speciality pharmaceuticals (large, injectable, protein-based molecules, or small molecules used to treat complex conditions such as cancer and hepatitis C or common chronic diseases such as rheumatoid arthritis and asthma). It is making steady progress in developing biosimilars in the oncology and immunology segments, even as it has products in the pipeline for rheumatology, dermatology, ophthalmology and respiratory disease treatments, says K. Nithyananda Reddy, Co-founder and Vice Chairman. "We are targeting a market opportunity of over $50 billion. We have a mix of biosimilar products in the pipeline," he says.
As other manufacturers also crowd the biosimilars space, Aurobindo is looking at diversifying towards the speciality disease business. And its export markets are crucial to its strategy of diversifying towards high-margin speciality generic (non-branded) formulations and the speciality diseases segment.
Bu hikaye Business Today India dergisinin September 18, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Business Today India dergisinin September 18, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
The EV Craze
The country’s growing luxury car market is seeing a shift with environmentally-conscious consumers betting on electric vehicles as a sustainable travel option. Though just 6%, the share of EVs in the luxury segment is rising rapidly
The Storage Boom
Data centres are being built at a frenetic pace in india as companies scramble to meet the ballooning demand from mobile phone users and firms adopting al. Can the country’s energy infrastructure keep up?
India Beckons
Owing to rising incomes in India and overall wealth expansion, luxury brands are wooing the country like never before
The Pearls of The Sea
Caviar, that rare food, is considered the epitome of fine dining. Here is everything that you need to know about it
66.Brand persona should define the core"
I’d say this was a strategic pivot. We had an iconic brand, but had, over time, evolved into diversified lines of businesses that could no longer be represented within the confines of our ‘name’.
Unwind in Style
Here is acomprehensive list of top tech picks that help you unwind by blending perfection in performance with luxury
A Lifelong Affair with Inspiration
In my art journey, the diversity of my acquisitions mirrored the expanding horizons of my understanding of art
Make it Bubbly
Champagne is much more than just a symbol of celebration and success. Know about its nuances beyond the bubbles
Palatial Splendour
Buoyed by renewed demand, sales of the glitzy mansions of the ultra-rich are surging like never before. Real estate majors are looking to capitalise on this by launching luxury offerings in record numbers
Of Beaches and Cream
GianChand Single Malt Whisky